Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.41 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11981378 | 0.83 | PARP10 (0.46) | PARP10PARP11PARP1HTR2CKDM4E | |
| SCHEMBL31393728 | 0.78 | PARP10 (0.42) | PARP10PARP11HTR2CHTR2AHTR2B | |
| SCHEMBL24317405 | 0.76 | PARP10 (0.41) | PARP10PARP11PARP1HTR2CHTR2A | |
| SCHEMBL30675774 | 0.76 | PARP10 (0.41) | PARP10PARP11PARP1HTR2CHTR2A | |
| SCHEMBL13181933 | 0.76 | KDM4E (0.47) | PARP10PARP11PARP1HTR2CHTR2A | |
| SCHEMBL31731343 | 0.75 | ALDH1A1 (0.39) | PARP10PARP11PARP1HTR2CHTR2A | |
| SCHEMBL19297120 | 0.73 | PARP1 (0.35) | PARP10PARP11PARP1HTR2CHTR2A | |
| SCHEMBL11981462 | 0.72 | KDM4E (0.44) | PARP10PARP11PARP1KDM4EALDH1A1 | |
| SCHEMBL18524349 | 0.71 | HTR2C (0.41) | HTR2CHTR2AHTR2B | |
| SCHEMBL31488066 | 0.70 | RXFP1 (0.46) | PARP10PARP11ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024028363-A1 | HETEROARYL CARBOXAMIDE AND RELATED GPR84 ANTAGONISTS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2024-02-08 | — | — | WO | disclosed |
| US-6413971-B1 | ANTIPROLIFERATIVE, -CARCINOGENIC, -TUMOR AND -DIABETIC AGENTS; BINDING TO OR MODULATING THE HUMAN KINASE INSERT-DOMAIN-CONTAINING RECEPTOR (KDR) OR THE MURINE FETAL LIVER KINASE 1 (FLK-1) RECEPTOR; VASCULOGENESIS; ANGIOGENESIS | PFIZER INC | 2002-07-02 | — | — | US | disclosed |
| US-6395733-B1 | ANTICANCER AGENTS; ANTIPROLIFERATIVE AGENTS | PFIZER INC | 2002-05-28 | — | — | US | disclosed |
| US-20020045630-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | ARNOLD LEE DANIEL (US) | 2002-04-18 | — | — | US | disclosed |
| CN-1237177-A | Fused bicyclic pyrimidine derivatives | PFIZER (US) | 1999-12-01 | — | — | CN | disclosed |
| EP-0946554-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0831829-A4 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER (US) | 1998-11-25 | — | — | EP | disclosed |
| WO-1998023613-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1998-06-04 | — | — | WO | disclosed |
| US-5736534-A | HYPERPROLIFERATIVE DISEASES; INHIBITORS OF PROTEIN-TYROSINE KINASES SUCH AS EPIDERMAL GROWTH FACTOR RECEPTOR; BRAIN, LUNG, BREAST CANCER; PSORIASIS AND BENIGN PROSTATE HYPERPLASIA | PFIZER INC. (US) | 1998-04-07 | — | — | US | disclosed |
| EP-0831829-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| CN-1141298-A | Pyrimidine-fused heterocyclic compound anti-cancer agents | PFIZER (US) | 1997-01-29 | — | — | CN | disclosed |
| CN-1141633-A | 4-heterocyclic substituted quinazoline derivatives, process for their preparation and their use as anticancer agents | PFIZER (US) | 1997-01-29 | — | — | CN | disclosed |
| WO-1996040142-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0746554-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995023141-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045630-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | REV1, DPYD, CCNA1 | PARP10 240/4885PARP11 33/4885PARP1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.